Intangible Assets

6 Months Ended

Jun. 30, 2026

Intangible Asset, Goodwill and Other [Abstract]

Note 15. Intangible Assets

EryDel Intangible Assets

The following table provides details of the carrying amount of the Company's indefinite-lived intangible asset (in thousands):


		(in thousands)
In-process research and development:
	Balance as of December 31, 2025	$	67,361
	Impairment charges		(67,361	)
	Balance as of June 30, 2026	$	—

The following table provides details of the carrying amount of the Company's finite-lived intangible asset (in thousands, except useful life):


			As of June 30, 2026								As of December 31, 2025
		Useful life	Cost		Accumulated Amortization			Net Carrying Value			Cost		Accumulated Amortization			Net Carrying Value
Finite life intangible assets:
	Trade name	21 years	$	460		(49	)	$	411		$	460		(26	)	$	434
	Foreign currency translation adjustments								36								(8	)
	Impairment charges								(447	)							—
	Total							$	—							$	426

In January 2026, the Company ceased clinical development of eDSP as the primary and secondary endpoints did not achieve statistical significance in its Phase 3 NEAT clinical trial. As a result, several of the assumptions used in determining the initial fair value have changed including expected cash flows and thus triggered the need for an interim impairment assessment as required under ASC 350. As a result, the fair value was determined to be significantly below its carrying value and the Company recognized a total impairment charge of $67.8 million for indefinite and finite-lived intangible assets during the six months ended June 30, 2026.